Cargando…

Use of glucarpidase (carboxypeptidase‐G2) in pediatric cancer patients: 11‐year experience of a tertiary center

Methotrexate is an essential drug in the treatment of childhood cancer that is not exempt from toxicities. Glucarpidase is a drug used to reduce the toxic concentration of plasma methotrexate in patients with delayed elimination or at risk of toxicity. We describe the characteristics of a cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vila, Rocío, Rubio‐San‐Simón, Alba, Zubiaur, Pablo, Navares‐Gómez, Marcos, Gómez‐Hernández, Patricia, Arce, Begoña, Madero, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Haematologic Malignancy ‐ Lymphoid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660123/ https://www.ncbi.nlm.nih.gov/pubmed/38024601 http://dx.doi.org/10.1002/jha2.799

Ejemplares similares

Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis
por: García‐Abellás, Patricia, et al.
Publicado: (2022)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Malignant DFFB isoform switching promotes leukemia survival in relapse pediatric T‐cell acute lymphoblastic leukemia
por: Enlund, Sabina, et al.
Publicado: (2022)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Immune reconstitution in children following chemotherapy for acute leukemia
por: Williams, Anthony P., et al.
Publicado: (2020)

The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia
por: Bhavsar‐Bhakta, Preeya, et al.
Publicado: (2021)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Marginal zone lymphoma expression of histidine‐rich glycoprotein correlates with improved survival
por: Persson Skare, Tor, et al.
Publicado: (2020)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome
por: Shen, Yandong, et al.
Publicado: (2021)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
por: Hillmen, Peter, et al.
Publicado: (2021)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

Family history of any cancer for childhood leukemia patients in Sweden
por: Li, Xinjun, et al.
Publicado: (2021)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021)

Clinical features and outcomes of duodenal‐type follicular lymphoma: A single‐center retrospective study
por: Kamijo, Kimimori, et al.
Publicado: (2022)

Primary central nervous system lymphoma: Inter‐compartmental progression
por: Raval, Vishal, et al.
Publicado: (2022)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia
por: Pfister, Verena, et al.
Publicado: (2022)

Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
por: Weissinger, Stephanie E., et al.
Publicado: (2022)

B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
por: Bock, Theresa, et al.
Publicado: (2022)

A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
por: Dittus, Christopher, et al.
Publicado: (2022)

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
por: García, Rolando, et al.
Publicado: (2022)

Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bi8orbkmi0nk0epupa5ll9s2ar